|
|
Article: GlycoDesign Ends GD0039 Trials, Moving Focus To Other Programs.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Senior Staff Writer
Following last week's American Society of Clinical Oncology meeting, at which it learned of toxicities in its Phase II GD0039 renal cancer trials, GlycoDesign Inc. said it is shelving the product.
"In the North American and [French] trials for renal cancer, this past week at ASCO we found out that we are seeing toxicity," said Sheri Zernentsch, investor relations manager at GlycoDesign. "Part of that toxicity was confusion and severe fatigue. Both ethically and as a drug development company, management had to decide, Do we go further or do we stop enrollment now?'"
The Toronto-based company decided to stop enrollment. After ...
Related newspaper, magazine, and journal articles:
|
|
Article: GLYCODesign Completes $16.35M Financing; Funds to Fuel ...
Business Wire;
May 6, 1998 ;
700+ words
... ... BUSINESS WIRE)--May 6, 1998--GLYCODesign Inc., a world leader in the biopharmaceutical ... capital investment in Toronto-based GLYCODesign to $35 million since the company ... President and Chief Executive Officer of GLYCODesign. "We have established a novel, viable ...
|
|